Abstract
F, Berger P, Popma J, Dangas G, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572–2578. 2. Smith J, Steinhubl S, Lincoff A, Coleman J, Lee T, Hillman R, Coller B. The rapid platelet function assay: an automated and quantitative cartridge-based method. Circulation 1999;99:620–625. 3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956–961. 4. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696. 5. The EPISTENT Investigators. Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87–92. 6. Chew D, Bhatt D, Lincoff A, Moliterno D, Brener B, Wolski K, Topol E. Defining the optimal activated clotting time during percutaneous coronary intervention—aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961–966.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
